Amir Muhammad, Yu Michael, He Peijian, Srinivasan Shanthi
Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Front Med (Lausanne). 2020 Feb 27;7:62. doi: 10.3389/fmed.2020.00062. eCollection 2020.
Non-alcoholic fatty liver disease represents a continuum of excessive hepatic steatosis, inflammation and fibrosis. It is a growing epidemic in the United States of America and worldwide. Progression of non-alcoholic fatty liver disease can lead to morbidity and mortality due to complications such as cirrhosis or hepatocellular carcinoma. Pathogenesis of non-alcoholic fatty liver disease is centered on increased hepatic lipogenesis and decreased hepatic lipolysis in the setting of hepatic and systemic insulin resistance. Adipose tissue and hepatic inflammation can further perpetuate the severity of illness. Currently there are no approved therapies for non-alcoholic fatty liver disease. Most of the drugs being explored for non-alcoholic fatty liver disease focus on classical pathogenic pathways surrounding hepatic lipid accumulation, inflammation or fibrosis. Studies have demonstrated that the autonomic nervous system innervating the liver plays a crucial role in regulation of hepatic lipid homeostasis, inflammation and fibrosis. Additionally, there is growing evidence that neurotrophic factors can modulate all stages of non-alcoholic fatty liver disease. Both the autonomic nervous system and neurotrophic factors are altered in patients and murine models of non-alcoholic fatty liver disease. In this review we focus on the pathophysiological role of the autonomic nervous system and neurotrophic factors that could be potential targets for novel therapeutic approaches to treat non-alcoholic fatty liver disease.
非酒精性脂肪性肝病表现为肝脂肪变性、炎症和纤维化程度不断加重的连续过程。在美国及全球范围内,它正日益流行。非酒精性脂肪性肝病的进展可因肝硬化或肝细胞癌等并发症导致发病和死亡。非酒精性脂肪性肝病的发病机制主要是在肝脏和全身胰岛素抵抗的情况下,肝脏脂肪生成增加和肝脏脂肪分解减少。脂肪组织和肝脏炎症会进一步加重病情的严重程度。目前尚无获批用于治疗非酒精性脂肪性肝病的疗法。大多数正在探索用于治疗非酒精性脂肪性肝病的药物都聚焦于围绕肝脏脂质蓄积、炎症或纤维化的经典致病途径。研究表明,支配肝脏的自主神经系统在调节肝脏脂质稳态、炎症和纤维化方面起着关键作用。此外,越来越多的证据表明,神经营养因子可调节非酒精性脂肪性肝病的各个阶段。在非酒精性脂肪性肝病患者和小鼠模型中,自主神经系统和神经营养因子均发生了改变。在本综述中,我们重点关注自主神经系统和神经营养因子的病理生理作用,它们可能是治疗非酒精性脂肪性肝病新治疗方法的潜在靶点。